Form 4: Unity Biotechnology CFO Lynne Sullivan Sells Shares to Cover Tax Obligations

Lynne Sullivan, CFO of Unity Biotechnology, sold 21,867 shares of common stock on April 2, 2025, to cover tax withholding obligations related to vesting Restricted Stock Units.

Summary

• On April 2, 2025, Lynne Marie Sullivan, CFO & Head of Corp. Dev. of Unity Biotechnology, sold 21,867 shares of the company's common stock at a price of $1.03 per share.
• The sale was executed under a Rule 10b5-1 trading plan to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units.
• Following the transaction, Sullivan directly owns 98,905 shares of Unity Biotechnology, which includes Restricted Stock Units that vest over time from the grant date.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale for tax purposes. It doesn't convey any strong positive or negative sentiment about the company's prospects.

Industry Context

Sales of shares to cover tax obligations are a routine part of equity compensation for executives. It is not necessarily indicative of the executive's sentiment about the company's future prospects.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, but is unlikely to have a significant impact as it is for tax purposes.

Key Dates

Keywords

Unity Biotechnology, UBX, Lynne Sullivan, CFO, stock sale, Form 4, Rule 10b5-1, Restricted Stock Units, tax withholding, insider trading